The medication is commonly used across therapeutic domains where additional symptomatic support is needed for various conditions.

It may assist with managing symptoms associated with acute or episodic changes, such as those related to inflammatory or irritative states and acute respiratory infections (ARIs). Clinical scenarios where the medicine supports patients include addressing non-healing wounds, trophic ulcers, and tissue damage from burns or frostbite, as well as managing conditions presenting with systemic imbalance and localized discomfort in chronic vascular and gynecological contexts. The therapeutic application is aimed at easing the overall symptom burden and supporting general well-being during symptomatic phases.

“The primary application is often focused on supporting the body’s recovery during periods when symptoms interfere with routine activities.”

---

Supportive Care: Symptoms related to Tissue Damage

Regulatory References

1. ГРЛС: Справочник РУ – Государственный реестр лекарственных средств

Populations Excluded from Use

The medicine is strictly contraindicated in individuals with known hypersensitivity or individual intolerance to the active substance, Sodium Deoxyribonucleate, or any other component of the formulation, representing an absolute exclusion criterion defined by regulatory authorities.

Age-Related Eligibility

Eligibility varies significantly based on the form administered. The local or topical solution is officially approved for use in children from birth (the first day of life) and adults. Conversely, the systemic (intramuscular) form is primarily intended for use in adults (18 years and older), establishing an age-based difference in eligibility by route of administration.

Restricted and Conditional Use Groups

Official regulatory documents mandate that the medicine be used with caution in the elderly population. Use is also restricted and requires caution in children younger than 23 months due to the absence of long-term safety data for this specific age group. For pregnant and breastfeeding women, use is categorized as restricted or conditional, considered only when the potential benefit is deemed to outweigh the potential risks, due to insufficient established clinical safety. Furthermore, the safety and efficacy are not established in patients with impaired renal function or impaired hepatic function.

The official regulatory profile for Sodium Deoxyribonucleate, the active ingredient in Деринат, details interactions across two primary domains: pharmacodynamic effects with systemic agents and physical incompatibility during local application. The regulatory documentation is silent on pharmacokinetic interactions, including those mediated by major metabolic enzymes or drug transporters.

Systemic Pharmacodynamic Interactions

Co-administration with certain systemic medicinal product classes results in documented additive or reinforcing effects. The regulatory label states that co-administration with Antibiotics and Antiviral Medicinal Products leads to a potentiation of their clinical efficacy. Furthermore, when co-administered with Cytostatics (including Anthracycline Antibiotics), the documented outcome is a reinforced clinical effect, which includes the mitigation of certain drug-associated toxicities.

Local Application Restrictions

Specific procedural constraints apply to the local application solution. The regulatory text dictates that the solution is physically incompatible with certain topical substances. To avoid a reduction in the drug's intended local effect, the solution must not be co-administered with Fat-based Ointments or Hydrogen Peroxide. This requirement establishes mandatory separation rules for concurrent topical use.

How Деринат Works

---

Activation of Core Immune Sensors via TLR9 Agonism

The foundational mechanism involves Sodium Deoxyribonucleate acting as an agonist for the intracellular defense receptor, Toll-like Receptor 9 (TLR9). This molecular interaction initiates a precise intracellular signaling cascade (e.g., NF-kappaB), which results in the immunomodulation and optimized function of key immune cells, thereby modulating host defense responses.

---

Mechanism-Driven Stimulation of Tissue Repair

Beyond immune modulation, the drug's mechanism stimulates processes that influence structural repair of tissue. This is achieved through the upregulation of growth factors (such as Amphiregulin), which accelerates the proliferation of progenitor cells and epithelialization. This mechanism provides the physiological basis for local tissue regeneration and influences the systemic process of hematopoiesis (blood cell formation and maturation) by engaging cellular regenerative machinery.

Instruction Map: How to use Деринат — Administration Guidelines

Administration of Sodium Deoxyribonucleate is formally structured around two distinct pharmaceutical strengths and their approved routes of delivery.

Property	Description
Route of administration:	Intramuscular (IM) or Subcutaneous (SC) injection (1.5% solution); Topical/Local Application (0.25% solution to mucosal surfaces).
Dosing schedule (Adults):	IM Dose: A standardized 5 ml (75 mg) of the 1.5% solution is administered per injection.
Frequency pattern:	Injections follow an intermittent schedule, with intervals ranging from 24 hours (daily) to 72 hours (every third day).
Age-group administration rules:	Pediatric IM Dosing: Dosage is adjusted based on age, with a reduced dose for patients under 10 years old. The full adult dose is used for patients 10 years and older. Local Use: Approved for children from the first days of life.
Special procedural conditions:	IM injection must be delivered slowly, requiring a duration of 1 to 2 minutes for the administration of the dose. No dilution or preparation is required.

---

Resulting Procedural Structure

The established protocol ensures precise delivery of the active substance, differentiating between systemic and localized treatment. The regimen for injection mandates a fixed adult dose and a slow administration rate, followed by a scheduled course ranging from 3 to 15 total injections. This structured approach outlines the parameters—including concentration, route, frequency, and total course length—that govern the standardized use of the medicine.

Research evidence / Overview of studies for Деринат

This section provides a summary of the clinical research and evidence base for Sodium Deoxyribonucleate, focusing on what types of studies have been conducted and the nature of the outcomes examined, based only on authoritative and peer-reviewed scientific sources. The text adheres to a strictly neutral tone and provides no individual clinical advice or treatment recommendations.

---

Evidence for Respiratory Infections (ARI and CAP)

Research has explored whether the compound has a role in managing conditions characterized by fluctuating or acute manifestations, such as Acute Respiratory Infections (ARI) and Community-Acquired Pneumonia (CAP). For ARIs, research includes short-term Randomized Controlled Trials (RCTs) and comparative clinical studies that evaluated the compound in adults and children. The outcomes examined were related to the time to resolution of key symptoms and the study of changes in mucosal immunity markers.

For Community-Acquired Pneumonia (CAP), the compound was evaluated in comparative clinical trials, often as an adjunct to conventional standard care. These studies examined the rate of change in inflammatory findings in the lungs and changes in immunological status markers over a defined treatment interval. Research highlights that the evidence is limited to short- to intermediate-term observation.

Evidence for Tissue Repair and Wound Management

Research has explored the compound's association with tissue repair patterns in conditions like non-healing wounds and trophic ulcers. The evidence base includes experimental studies using animal models and cell cultures. Clinical data often come from observational cohorts and case series rather than large-scale RCTs. These studies monitored physical outcomes such as the measurements of changes in wound or ulcer area over defined time intervals. However, evidence quality varies across studies, and certainty remains low for definitive conclusions regarding long-term outcomes.

Areas of Research Uncertainty and Gaps

A consistent pattern across the evidence base is that sample sizes were modest in many clinical investigations. Consequently, the generalizability of results applies mainly to the specific populations studied. Data for certain subgroups remain insufficient, and comparative evidence against established international standard-of-care protocols may be lacking or mixed. These limitations mean that certainty remains low for several applications, and the data are still emerging. Further large-scale, methodologically rigorous research is ongoing to address these gaps in the broader scientific literature.

Key Studies & References

1. Multicenter Double Blinded Placebo-controlled Randomized Study to Evaluate Clinical Efficacy, Tolerability, Safety of Medical Product Derinat®, Solution for External and Local Use 0.25% in Acute Infections of Respiratory System in Children (NCT04149431)
2. The natural immunomodular sodium deoxyribonucleate as a drug to treat influenza and acute respiratory viral infection in children (results of preclinical and clinical trials)
3. Деринат – ГРЛС: Справочник РУ – Государственный реестр лекарственных средств (Derinat – GRLS: Register of Medicinal Products, confirming official registration and indications)

Common questions about Деринат (FAQ)

Q: Is the nasal drop formulation medically considered to be the same as the injection or external solution?

According to official product information, the various formulations of Деринат all contain the same active substance, Sodium Deoxyribonucleate. However, they are different preparations intended for specific routes of administration.

For example, the 0.25% solution is approved for local use on surfaces like the nasal passages, while the 1.5% solution is approved for systemic (injection) use only.

Q: Is the medicine intended for immediate symptom relief or for long-term immune support?

The medicine is officially characterized as an immunomodulating and regenerative agent. Its core function is described as supporting the body's natural protective systems and enhancing its overall capacity for recovery.

The official characterization of its core function emphasizes strengthening defenses and aiding recovery, which aligns with long-term immune support rather than immediate symptom relief.

Q: Are there any known long-term safety concerns associated with prolonged use of the medicine?

Regulatory reviews of the drug indicate that the available clinical evidence is often limited to short- to intermediate-term observation. Official documents note that data regarding long-term safety is insufficient for certain patient subgroups.

It is important that the use of the medicine aligns with the defined duration specified in the official instructions.

Q: Is Деринат classified as a prescription-only medicine or is it available over the counter?

The regulatory status varies depending on the pharmaceutical form. The systemic (injection) solution (1.5%) is typically classified as prescription-only.

Conversely, the local application solution (0.25%) is often available for purchase without a prescription. The regulatory classification may vary by region.

Q: What are the main conditions that regulatory documents state Деринат is intended to treat?

The specific and complete list of officially approved indications (the conditions the medicine is approved to treat) is determined by the regulatory authority.

This comprehensive list is detailed in the manufacturer's official Instructions for Medical Use, typically located in the 'Indications' section.

Q: Does Деринат cause drowsiness or affect the ability to concentrate or drive?

Official regulatory summaries of adverse events typically focus on the most commonly reported reactions associated with the drug.

These summaries do not list drowsiness or adverse effects on the ability to concentrate or drive among the common or expected side effects.

Q: Are there any food or drink restrictions that should be followed while using Деринат?

The regulatory documentation regarding interactions is primarily focused on concurrent use with other topical or systemic medicines.

The official product information is silent regarding any specific restrictions related to food or general drink consumption during the use of this medicine.

Q: Does it interact with common over-the-counter pain relievers or fever-reducing drugs?

Official regulatory documentation details known interactions with antibiotics, antiviral agents, and cytostatics.

However, the documentation does not detail specific pharmacokinetic interactions with common over-the-counter medicines such as non-steroidal anti-inflammatory drugs (NSAIDs) or Paracetamol.

Q: Where can I find the official regulatory document summary about the clinical evidence for the medicine?

The most complete and authoritative regulatory summary of the medicine, including clinical evidence and safety data, is contained within the officially approved Instructions for Medical Use.

This document is the equivalent of a Patient Information Leaflet or Summary of Product Characteristics (SmPC) and is the definitive regulatory source.

Q: Does the medicine contain antibodies or other components derived from blood?

The medicine is officially described as being composed of low molecular native fragments of DNA. This active component is derived from fish milt.

Official regulatory descriptions confirm that the medicine does not contain antibodies or any components derived from human or animal blood.

Q: How long after the bottle is opened should Деринат be thrown away?

The official documentation specifies the total shelf-life for the unopened product.

The specific time period for use after the bottle is first opened (the in-use stability) is determined by the manufacturer’s stability data and is typically listed in the storage section of the full Instructions for Medical Use.

How to Store and Dispose of Деринат (Sodium Deoxyribonucleate)

The storage and disposal of Деринат must adhere strictly to the conditions specified in the official regulatory labeling.

---

Official Storage Requirements

Requirement	Specific Condition
Temperature	Store between +4, C and +20, C.
Protection	Keep protected from light and moisture.
Container	Store in the original primary packaging.
Prohibition	Do not freeze. The product is prohibited from use if frozen.
Child Safety	Keep out of the reach of children.

---

Disposal

Shelf-Life: The medicine has a labeled shelf-life of 5 years.

Unused or expired Деринат and all associated waste materials must be disposed of in accordance with local legal requirements for pharmaceutical waste handling.